Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Designed to Evaluate the Safety, Tolerability, and Effect of a Single, Rising Dose of Intravenous AL-208, Followed by a Placebo-Controlled, Double-Blind, Parallel-Group Evaluation of a Single Dose of AL-208, on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery.

NCT00404014 is registered in ClinicalTrials.gov with Allon Therapeutics as lead sponsor.

NCT NCT00404014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00404014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Designed to Evaluate the Safety, Tolerability, and Effect of a Single, Rising Dose of Intravenous AL-208, Followed by a Placebo-Controlled, Double-Blind, Parallel-Group Evaluation of a Single Dose of AL-208, on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery.
Lead sponsor
Allon Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2006
Completion date
June 30, 2008
Enrollment
234 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

mild cognitive impairment